Literature DB >> 12031657

Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells.

Phennapha Klangsinsirikul1, Nigel H Russell.   

Abstract

OBJECTIVE: To assess the numbers and function of dendritic cell (DC) subsets and T helper cells in bone marrow (BM) and peripheral blood stem cell (PBSC) harvests. PATIENTS AND METHODS: DC subsets in stem cell grafts were analyzed using three-color flow cytometry. Intracellular cytokine staining and the staining of IL-12Rbeta2 were used for determining the proportion of Th1-, Th2-, and IL-12-producing DC in the grafts. The ability of DC1 and DC2 to induce T-cell proliferation and cytokine secretion were studied using thymidine incorporation and ELISA techniques.
RESULTS: PBSC recipients received a significantly higher number of DC2 than BM recipients and a lower proportion of IL-12-producing DC. Purified DC1 from both BM and PBSC grafts were capable of inducing proliferation of allogeneic T cells and also induced a predominant Th1 response when cultured with CD4(+)/CD45RA(+) cells. In contrast, DC2 induced a predominant Th2 cytokine response. PBSC grafts contained a higher number of both Th1 and Th2 cells compared to BM grafts; however, as a consequence of the increased number of Th2 cells the ratio of Th1:Th2 cells in PBSC grafts was 1.1:1 compared to 9.8:1 in BM. Furthermore, following in vitro activation of T cells, PBSC grafts contained a lower proportion of IL-12Rbeta2(+) T cells.
CONCLUSION: G-CSF does not have a direct effect on DC function but acts to increase the numbers of DC2 in the blood of PBSC donors. This is associated with a higher proportion of Th2 cells present in PBSC grafts and T cells in PBSC grafts were less likely to develop a Th1 response following in vitro activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12031657     DOI: 10.1016/s0301-472x(02)00785-3

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  14 in total

Review 1.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Authors:  U Deotare; G Al-Dawsari; S Couban; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 3.  Early B lymphocyte development: Similarities and differences in human and mouse.

Authors:  Michiko Ichii; Kenji Oritani; Yuzuru Kanakura
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

4.  Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells.

Authors:  P J Mannon; F Leon; I J Fuss; B A Walter; M Begnami; M Quezado; Z Yang; C Yi; C Groden; J Friend; R L Hornung; M Brown; S Gurprasad; B Kelsall; W Strober
Journal:  Clin Exp Immunol       Date:  2008-12-15       Impact factor: 4.330

Review 5.  Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden?

Authors:  J J Auletta; S M Devine; E K Waller
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

6.  Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Ming-Rui Huo; Xiao-Jun Huang
Journal:  J Clin Immunol       Date:  2009-05-22       Impact factor: 8.317

7.  Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.

Authors:  Andreas Lundqvist; Aleah L Smith; Yoshiyuki Takahashi; Susan Wong; Erkut Bahceci; Lisa Cook; Catalina Ramos; Abdul Tawab; J Philip McCoy; Elizabeth J Read; Hanh M Khuu; Charles D Bolan; Jungnam Joo; Nancy Geller; Susan F Leitman; Gary Calandra; Cynthia Dunbar; Roger Kurlander; Richard W Childs
Journal:  J Immunol       Date:  2013-11-15       Impact factor: 5.422

8.  A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas.

Authors:  Chitra Hosing; Mark F Munsell; James M Reuben; Uday Popat; Bang-Ning Lee; Hui Gao; Martin Körbling; Elizabeth J Shpall; Partow Kebriaei; Amin Alousi; Marcos De Lima; John McMannis; Muzaffar Qazilbash; Paolo Anderlini; Sergio Giralt; Richard E Champlin; Issa Khouri
Journal:  J Blood Med       Date:  2010-04-14

9.  Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application.

Authors:  Sya N Ukena; Sarvari Velaga; Lilia Goudeva; Philipp Ivanyi; Sven Olek; Christine S Falk; Arnold Ganser; Anke Franzke
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

Review 10.  Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection.

Authors:  Bao-Guo Xiao; Chuan-Zhen Lu; Hans Link
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.